Abstract：Objective evaluate the long-term efficacy of the recombinant hepatitis B vaccines （HBV）among the newborns with vaccination at birth. Methods During 1996-1997,135 newborns were selected from Deqing according to the inclusion criterion. They were divided into 2 groups: a group of 35 newborns whose mother was HBsAg positive） and a group of 100 newbornswhose mother was HBsAg negative. All 135 newborns routinely received 3 doses of yeast -derived hepatitis B vaccines （i.e. the first dose at birth,the second dose at 1 month old,and the third dose at 6 months old）. Serological markers to HBV were repeatedly assessed at 3 follow-up stages （i.e. the first follow-up at 12 months,the second follow-up at 2010,the third follow-up at 2012）. Results Participants remained in the study at 3 follow-upstages were 123 （91.11%）,95（70.37%）and 46（34.07%）respectively. Participants' serum HBsAg were negative at all 3 follow-up stages. Among participants whose mothers were HBsAg positive,3 participants were found to be HBcAb positive in 2010,and no new HBcAb positive participants were found in 2012. The rates of HBsAb positive at 3 follow-up stages were 88.89%,81.48%,and 80.00% respectively. The HBsAb geometric mean concentrations （GMCs） of participants at their 12 months old were significantly positively associated with those in 2010 and those in 2012（P<0.05）. Among participants whose mothers were HBsAg negative,no HBcAb positive participants were found. The rates of HBsAb positive at 3 follow-up stages were 91.18%,54.41%,and 52.78% respectively. No correlation was found among HBsAb GMCs of participants at 12 months old,in 2010 and in 2012. No correlation was found between boost vaccination and the rate of HBsAg positive,after adjustment of the HBsAg status of their mothers. Conclusion The efficacy of the yeast-derived HBV could sustain for at least 13-15 years,and the general population do not need booster immunization. After the 3-dose immunization,the HBsAb levels of the healthy mothers' 12-months-old children were related to those of their adolescence.
董晓莲, 唐智峰, 王学才, 陈颖峰, 陈胜玉, 王晓丽, 范建良, 郑英杰. 新生儿接种重组乙型肝炎疫苗长期效果观察[J]. 预防医学, 2017, 29(5): 438-442.
DONG Xiao-lian, TANG Zhi-feng, WANG Xue-cai, CHEN Ying-feng, CHEN Sheng-yu, WANG Xiao-li, FAN Jian-liang, ZHENG Ying-jie. An observation on the long-term efficacy of recombinant hepatitis B vaccines among the newborns. Preventive Medicine, 2017, 29(5): 438-442.
[1] EDMUNDS W J, MEDLEY G F, NOKES D J, et al. The influence of age on the development of the hepatitis B carrier state [J]. Proc Biol Sci,1993,253（1337）：197-201. [2] LEE C, GONG Y, BROK J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen：systematic review and meta-analysis[J]. BMJ, 2006, 332（7537）：328-336. [3] 沈立萍,毕胜利. 我国乙型肝炎疫苗免疫效果评价及加强免疫策略研究进展[J].中国疫苗和免疫,2011,17（6）：545-548. [4] 翟祥军,汪华,朱凤才,等. 江苏省农村地区儿童乙型肝炎疫苗免疫效果及其影响因素研究[J].中华流行病学杂志,2007,28（4）：322-325. [5] ZHU C L, LIU P, CHEN T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination [J]. Vaccine, 2011, 29（44）：7835-7841. [6] YUEN M F,LIM W L,CHAN A O, et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children[J]. Clin Gastro Hepatol, 2004, 2（10）：941-945. [7] POOROLAJAL J, MAHMOODI M, MAJDZADEH R, et al. Long-term protection provided by hepatitis B vaccine and need for booster dose：a meta-analysis[J].Vaccine, 2010, 28（3）： 623-631. [8] POOVORAWAN Y, CHONGSRISAWAT V, THEAMBOONLERS A, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers[J]. J Infect Dis, 2009, 200（1）：33-38. [9] BANATVALA J, DAMME P, OCHEN S. Lifelong protection against hepatitis B：the role of immunogenicity in immune memory[J]. Vaccine, 2000, 19（7/8）：877-885. [10] 周绍英,边国宁,马瑞,等. 不同乙型肝炎疫苗新生儿免疫应答的动态变化研究[J]. 浙江预防医学,2015,27（5）：466-476. [11] MCMAHON B J, DENTINGER C M, BRUDEN D, et al. Antibody levels and protection after hepatitis B vaccine：results of a 22-year follow-up study and response to a booster dose [J]. J Infect Dis,2009,200（9）：1390-1396. [12] ZANETTI A R, MARIANO A, ROMANÖ L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster：an Italian multicentre study[J]. Lancet,2005,366（9494）：1379-1384. [13] 王学才,郑英杰,董晓莲,等. 中小学生乙型肝炎表面抗原阳性的影响因素病例对照研究[J]. 浙江预防医学,2012, 24（5）：11-19. [14] 蒋征刚,陈恩富,李倩,等.1剂次不同剂量乙肝疫苗加强免疫效果观察[J]. 浙江预防医学,2011,23（6）：1-4. [15] LU C Y, NI Y H, CHIANG B L,et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization[J]. J Infect Dis,2008（197）：1419- 1426. [16] LANKARANI K B.The necessity of booster vaccination after neonatal hepatitis B vaccination[J]. Hepat Mon,2011,11（6）：419-421. [17] 沈灵智,姚军.乙型肝炎疫苗加强免疫策略研究进展[J]. 浙江预防医学,2011,23（12）:22-25.
